Monoclonal antibodies such as omalizumab, the anti-IgE monoclonal antibody, are approved for asthmatic patients ≥ 6 years old, but there is limited evidence for its use in ABPA in children with CF [170]. The gene discussed is IGHE; the disease is cystic fibrosis.